Healthcare's Shift to Prevention Gains Momentum as Markets Reach Critical Mass October 21, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Longevity science advances reveal how genes from supercentenarians can reverse cardiac aging[1], while AI diagnostics platforms expand across U.S. healthcare systems to detect disease years before symptoms emerge[2]. The convergence of genomic editing, predictive analytics, and personalized drug delivery is repositioning healthcare from crisis intervention to continuous optimization, creating openings for companies positioned at this intersection: Avant Technologies, Inc. (OTCQB: AVAI), Humana Inc. (NYSE: HUM), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corporation (NASDAQ: MNKD), and CRISPR Therapeutics (NASDAQ: CRSP). According to Precedence Research, the precision medicine market is projected to surge from $102 billion in 2024 to $463 billion by 2034[3], driven by chronic disease burden and genomic sequencing breakthroughs. FDA discussions around accelerated approval pathways now enable pooling clinical data to expedite biologics licenses for gene therapies, signaling regulatory momentum that favors early entrants addressing unmet medical needs through targeted genetic interventions. Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic transformation toward a partnership-driven business model that could position the company at the intersection of disease detection and advanced cell-based therapeutics. Through strategic joint ventures, Avant appears to be building what may become an integrated healthcare platform, identifying genetically modified cell lines to address hard to treat diseases while developing targeted cell-based treatments through innovative biotechnology partnerships. Back in June 2025, Avant announced plans to create a new company to house a joint venture, partnership, or acquisition as it explores expanding its interests in a diabetes development program offering potential treatment opportunities. Chris Winter, CEO of Avant, said, "We are exploring several promising opportunities to get involved in the development of a treatment for diabetes globally." Avant's most clinically advanced partnership, Klothonova, Inc., is a 50/50 joint venture with Singapore-based cell therapy pioneer Austrianova that demonstrates the company's treatment development capabilities. Klothonova focuses on developing cell-based therapies utilizing encapsulated Klotho-producing cells targeting age-related diseases while also developing anti-aging therapies for the promotion of longevity and quality of life. The program successfully completed its initial R&D proof of concept phase, where Austrianova generated genetically modified human cells that over-produce the Klotho protein. These cells were successfully encapsulated in Austrianova's proprietary Cell-in-a-Box® technology and shown to produce the Klotho protein continuously, demonstrating the feasibility of this approach. The program is now advancing to GMP-grade production for potential preclinical and clinical studies, with preparations underway at Austrianova's ISO9001:2015 compliant facility. "The R&D level proof of concept study provides a clear rationale for the program, giving a green light to move to GMP studies," said Winter. "By prioritizing GMP compliance from the outset, Klothonova is committed to delivering safe, effective treatments that could transform the landscape of age-related disease management." The scientific foundation for Klotho-based therapies appears compelling. Studies show higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lower Klotho levels had 31% higher mortality rates. Critically, natural Klotho levels drop by 50% after age 40, potentially creating substantial therapeutic opportunities for this "longevity protein" that affects brain, heart, kidney, and immune function. Austrianova's cell-encapsulation platform is backed by over 50 peer-reviewed publications and 30+ years of development. The technology represents an approach that has been studied for multiple therapeutic protein applications. While Avant has not disclosed specific details about which approaches it may pursue for its diabetes treatment exploration, the company's partnerships demonstrate capabilities in both disease detection and cell-based therapeutic development. The potential market opportunity spans multiple therapeutic areas. The global Alzheimer's market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. The cell-based therapy market could reach $44 billion globally. "Our transition to a partnership-driven model represents a transformative step for Avant," said Winter. "By combining forces with top-tier experts, we're not just identifying diseases. We're actively developing solutions that could change lives." CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ Humana Inc. (NYSE: HUM) has committed over $12 million through its philanthropic arm to combat social isolation affecting 29% of American seniors, a condition that increases dementia risk by 50%. The Humana Foundation's 2025 grants will fund national organizations including the National Council on Aging ($2.5M), Volunteers of America ($1.46M), and the Elizabeth Dole Foundation ($3M) to scale proven interventions addressing depression, substance abuse, and caregiver mental wellness among veterans. The foundation is also deploying regional programs across Florida, Texas, Kentucky, and Louisiana targeting the 1.1 million seniors living alone in these states. "We want every senior to feel seen, supported and connected—to live not just longer but better," said Tiffany Benjamin, CEO of the Humana Foundation. "Too many of our nation's seniors live alone and with depression, PTSD or chronic illness that limits their mobility and socialization. We're expanding proven interventions and investing in data and technology solutions to help more people improve their lives." Beyond emotional health initiatives, the foundation awarded four research grants totaling $1.1 million to institutions including the University of North Carolina at Chapel Hill, University of Kentucky, Harvard Medical School, and AcademyHealth to develop AI-driven bias reduction tools for medical training and county-level food insecurity mapping. With 40,000 seniors living alone in Louisville alone and over 230,000 Humana Inc. members living with depression nationwide, these investments address critical gaps in both mental health infrastructure and nutritional security for aging populations. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has secured rolling review status from the FDA for its Biologics License Application for povetacicept in IgA nephropathy, with the first module submission expected before year-end and full BLA completion targeted for the first half of 2026. The company simultaneously initiated OLYMPUS, a Phase 2b/3 pivotal study of povetacicept in primary membranous nephropathy, marking the second indication for this dual BAFF/APRIL antagonist that represents the only such inhibitor in pivotal trials for multiple kidney diseases. Vertex will present 48-week efficacy and safety data from the RUBY-3 trial at American Society of Nephrology Kidney Week 2025 on November 8, showcasing results from adults with IgAN and pMN who received subcutaneous dosing every four weeks. "We are very pleased with the continued momentum in our pove program across multiple indications," said Carmen Bozic, M.D., Executive Vice President of Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "Breakthrough designation, rolling submission for the IgAN BLA, and initiation of the second pivotal trial for pove, in pMN, bring us closer to getting this potential best-in-class therapy to patients with these serious diseases." The RAINIER Phase 3 trial in approximately 480 IgAN patients is designed with a pre-planned interim analysis at 36 weeks measuring urine protein-to-creatinine ratio changes that could support accelerated approval, while the two-year primary endpoint assesses total eGFR slope through Week 104. IgAN affects approximately 300,000 people in the United States and Europe with up to 72% progressing to end-stage renal disease within 20 years, while pMN impacts 150,000 patients across these regions with no specifically approved therapies for either condition. Vertex will host an investor event on November 8 from 7:00-8:15 p.m. CST in Houston to discuss updated kidney disease portfolio data alongside the povetacicept results. MannKind Corporation (NASDAQ: MNKD) has completed its acquisition of scPharmaceuticals Inc., adding FUROSCIX (furosemide injection) to its commercial portfolio and positioning the company as a diversified biopharmaceutical enterprise with an annualized revenue run rate exceeding $370 million based on Q2 2025 results. The tender offer closed on October 6, 2025 with approximately 73.47% of outstanding scPharmaceuticals shares tendered, satisfying all conditions for the statutory merger that values the transaction at $5.35 per share in cash plus contingent value rights worth up to $1.00 per share upon achieving regulatory and sales milestones. FUROSCIX, approved for treating edema in chronic heart failure and chronic kidney disease patients, expands MannKind's cardiometabolic franchise alongside Afrezza, V-Go, and Tyvaso DPI-related revenues. "With the close of the acquisition, MannKind now has multiple revenue lines with strong growth potential, a deepening presence in cardiometabolic care, and a commercial infrastructure ready to support the next phase of growth," said Michael Castagna, PharmD, CEO of MannKind Corporation. "This milestone accelerates our strategy to build a patient-centric company that delivers innovative therapies for chronic disease." The strategic combination integrates scPharmaceuticals' cardiovascular expertise with MannKind's endocrinology infrastructure to expand FUROSCIX distribution among nephrologists and cardiologists while advancing the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application filed in Q3 2025. MannKind's late-stage pipeline includes Inhaled Clofazimine for nontuberculous mycobacterial lung disease and nintedanib DPI for idiopathic pulmonary fibrosis, creating potential for sustained long-term value creation. The acquisition strengthens MannKind's position to serve patients with chronic diseases requiring daily management through drug-device combination therapies. CRISPR Therapeutics (NASDAQ: CRSP) has unveiled preclinical data for CTX460 demonstrating correction of the SERPINA1-E342K mutation underlying alpha-1 antitrypsin deficiency using its novel SyNTase gene editing platform, with clinical trial initiation planned for mid-2026. In both NSG-PiZ mouse and humanized PiZ rat disease models, a single 0.5 mg/kg dose of the lipid nanoparticle-encapsulated therapy achieved over 90% mRNA correction, yielded a greater than 5-fold increase in total serum AAT levels with an M-AAT:Z-AAT ratio exceeding 99%, and maintained durable editing for up to 9 weeks. The data were presented October 10, 2025 in an oral presentation titled "Single-dose in vivo gene correction of AATD via LNP-delivered SyNTase editors" at the European Society of Gene and Cell Therapy 2025 Annual Congress. "Alpha-1 antitrypsin deficiency remains an area of significant unmet need, with current treatments unable to address the underlying genetic cause. The goal of therapy should be to normalize alpha-1 antitrypsin levels," said Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics. "The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency. The data support CTX460's potential best-in-class profile in AATD, and we look forward to advancing CTX460 into the clinic in mid-2026." AATD affects patients carrying two copies of the PiZ variant (ZZ genotype) who typically maintain serum AAT levels of only 5-6 mM compared to normal levels exceeding 20 mM, leaving lungs vulnerable to emphysema while misfolded Z-AAT polymers accumulate in the liver contributing to fibrosis and cirrhosis. Current standard-of-care requires weekly intravenous infusions of purified M-AAT protein to mitigate lung symptoms without addressing the genetic cause, creating demand for therapies that normalize AAT levels to prevent disease progression. CTX460 represents the first investigational candidate to emerge from the SyNTase editing platform, with CRISPR Therapeutics positioning the technology as applicable to both rare and common disorders beyond AATD. Sources: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. -- SOURCES CITED 1. https://medicalxpress.com/news/2025-10-longevity-gene-supercentenarians-disease-rapid.html 2. https://www.globenewswire.com/news-release/2025/10/10/3164756/0/en/United-States-Artificial-Intelligence-in-Diagnostics-Market-Research-Report-2025-2033-Precision-Medicine-Advanced-Imaging-Analytics-and-AI-Enabled-Clinical-Decision-Support-Spur-Ex.html 3. https://www.globenewswire.com/news-release/2025/10/10/3164977/0/en/Precision-Medicine-Market-Size-Booms-at-16-35-CAGR-Expected-to-Reach-USD-463-11-Billion-by-2034.html
Healthcare's Shift to Prevention Gains Momentum as Markets Reach Critical Mass October 21, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Longevity science advances reveal how genes from supercentenarians can reverse cardiac aging[1], while AI diagnostics platforms expand across U.S. healthcare systems to detect disease years before symptoms emerge[2]. The convergence of genomic editing, predictive analytics, and personalized drug delivery is repositioning healthcare from crisis intervention to continuous optimization, creating openings for companies positioned at this intersection: Avant Technologies, Inc. (OTCQB: AVAI), Humana Inc. (NYSE: HUM), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corporation (NASDAQ: MNKD), and CRISPR Therapeutics (NASDAQ: CRSP). According to Precedence Research, the precision medicine market is projected to surge from $102 billion in 2024 to $463 billion by 2034[3], driven by chronic disease burden and genomic sequencing breakthroughs. FDA discussions around accelerated approval pathways now enable pooling clinical data to expedite biologics licenses for gene therapies, signaling regulatory momentum that favors early entrants addressing unmet medical needs through targeted genetic interventions. Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic transformation toward a partnership-driven business model that could position the company at the intersection of disease detection and advanced cell-based therapeutics. Through strategic joint ventures, Avant appears to be building what may become an integrated healthcare platform, identifying genetically modified cell lines to address hard to treat diseases while developing targeted cell-based treatments through innovative biotechnology partnerships. Back in June 2025, Avant announced plans to create a new company to house a joint venture, partnership, or acquisition as it explores expanding its interests in a diabetes development program offering potential treatment opportunities. Chris Winter, CEO of Avant, said, "We are exploring several promising opportunities to get involved in the development of a treatment for diabetes globally." Avant's most clinically advanced partnership, Klothonova, Inc., is a 50/50 joint venture with Singapore-based cell therapy pioneer Austrianova that demonstrates the company's treatment development capabilities. Klothonova focuses on developing cell-based therapies utilizing encapsulated Klotho-producing cells targeting age-related diseases while also developing anti-aging therapies for the promotion of longevity and quality of life. The program successfully completed its initial R&D proof of concept phase, where Austrianova generated genetically modified human cells that over-produce the Klotho protein. These cells were successfully encapsulated in Austrianova's proprietary Cell-in-a-Box® technology and shown to produce the Klotho protein continuously, demonstrating the feasibility of this approach. The program is now advancing to GMP-grade production for potential preclinical and clinical studies, with preparations underway at Austrianova's ISO9001:2015 compliant facility. "The R&D level proof of concept study provides a clear rationale for the program, giving a green light to move to GMP studies," said Winter. "By prioritizing GMP compliance from the outset, Klothonova is committed to delivering safe, effective treatments that could transform the landscape of age-related disease management." The scientific foundation for Klotho-based therapies appears compelling. Studies show higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lower Klotho levels had 31% higher mortality rates. Critically, natural Klotho levels drop by 50% after age 40, potentially creating substantial therapeutic opportunities for this "longevity protein" that affects brain, heart, kidney, and immune function. Austrianova's cell-encapsulation platform is backed by over 50 peer-reviewed publications and 30+ years of development. The technology represents an approach that has been studied for multiple therapeutic protein applications. While Avant has not disclosed specific details about which approaches it may pursue for its diabetes treatment exploration, the company's partnerships demonstrate capabilities in both disease detection and cell-based therapeutic development. The potential market opportunity spans multiple therapeutic areas. The global Alzheimer's market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. The cell-based therapy market could reach $44 billion globally. "Our transition to a partnership-driven model represents a transformative step for Avant," said Winter. "By combining forces with top-tier experts, we're not just identifying diseases. We're actively developing solutions that could change lives." CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ Humana Inc. (NYSE: HUM) has committed over $12 million through its philanthropic arm to combat social isolation affecting 29% of American seniors, a condition that increases dementia risk by 50%. The Humana Foundation's 2025 grants will fund national organizations including the National Council on Aging ($2.5M), Volunteers of America ($1.46M), and the Elizabeth Dole Foundation ($3M) to scale proven interventions addressing depression, substance abuse, and caregiver mental wellness among veterans. The foundation is also deploying regional programs across Florida, Texas, Kentucky, and Louisiana targeting the 1.1 million seniors living alone in these states. "We want every senior to feel seen, supported and connected—to live not just longer but better," said Tiffany Benjamin, CEO of the Humana Foundation. "Too many of our nation's seniors live alone and with depression, PTSD or chronic illness that limits their mobility and socialization. We're expanding proven interventions and investing in data and technology solutions to help more people improve their lives." Beyond emotional health initiatives, the foundation awarded four research grants totaling $1.1 million to institutions including the University of North Carolina at Chapel Hill, University of Kentucky, Harvard Medical School, and AcademyHealth to develop AI-driven bias reduction tools for medical training and county-level food insecurity mapping. With 40,000 seniors living alone in Louisville alone and over 230,000 Humana Inc. members living with depression nationwide, these investments address critical gaps in both mental health infrastructure and nutritional security for aging populations. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has secured rolling review status from the FDA for its Biologics License Application for povetacicept in IgA nephropathy, with the first module submission expected before year-end and full BLA completion targeted for the first half of 2026. The company simultaneously initiated OLYMPUS, a Phase 2b/3 pivotal study of povetacicept in primary membranous nephropathy, marking the second indication for this dual BAFF/APRIL antagonist that represents the only such inhibitor in pivotal trials for multiple kidney diseases. Vertex will present 48-week efficacy and safety data from the RUBY-3 trial at American Society of Nephrology Kidney Week 2025 on November 8, showcasing results from adults with IgAN and pMN who received subcutaneous dosing every four weeks. "We are very pleased with the continued momentum in our pove program across multiple indications," said Carmen Bozic, M.D., Executive Vice President of Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "Breakthrough designation, rolling submission for the IgAN BLA, and initiation of the second pivotal trial for pove, in pMN, bring us closer to getting this potential best-in-class therapy to patients with these serious diseases." The RAINIER Phase 3 trial in approximately 480 IgAN patients is designed with a pre-planned interim analysis at 36 weeks measuring urine protein-to-creatinine ratio changes that could support accelerated approval, while the two-year primary endpoint assesses total eGFR slope through Week 104. IgAN affects approximately 300,000 people in the United States and Europe with up to 72% progressing to end-stage renal disease within 20 years, while pMN impacts 150,000 patients across these regions with no specifically approved therapies for either condition. Vertex will host an investor event on November 8 from 7:00-8:15 p.m. CST in Houston to discuss updated kidney disease portfolio data alongside the povetacicept results. MannKind Corporation (NASDAQ: MNKD) has completed its acquisition of scPharmaceuticals Inc., adding FUROSCIX (furosemide injection) to its commercial portfolio and positioning the company as a diversified biopharmaceutical enterprise with an annualized revenue run rate exceeding $370 million based on Q2 2025 results. The tender offer closed on October 6, 2025 with approximately 73.47% of outstanding scPharmaceuticals shares tendered, satisfying all conditions for the statutory merger that values the transaction at $5.35 per share in cash plus contingent value rights worth up to $1.00 per share upon achieving regulatory and sales milestones. FUROSCIX, approved for treating edema in chronic heart failure and chronic kidney disease patients, expands MannKind's cardiometabolic franchise alongside Afrezza, V-Go, and Tyvaso DPI-related revenues. "With the close of the acquisition, MannKind now has multiple revenue lines with strong growth potential, a deepening presence in cardiometabolic care, and a commercial infrastructure ready to support the next phase of growth," said Michael Castagna, PharmD, CEO of MannKind Corporation. "This milestone accelerates our strategy to build a patient-centric company that delivers innovative therapies for chronic disease." The strategic combination integrates scPharmaceuticals' cardiovascular expertise with MannKind's endocrinology infrastructure to expand FUROSCIX distribution among nephrologists and cardiologists while advancing the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application filed in Q3 2025. MannKind's late-stage pipeline includes Inhaled Clofazimine for nontuberculous mycobacterial lung disease and nintedanib DPI for idiopathic pulmonary fibrosis, creating potential for sustained long-term value creation. The acquisition strengthens MannKind's position to serve patients with chronic diseases requiring daily management through drug-device combination therapies. CRISPR Therapeutics (NASDAQ: CRSP) has unveiled preclinical data for CTX460 demonstrating correction of the SERPINA1-E342K mutation underlying alpha-1 antitrypsin deficiency using its novel SyNTase gene editing platform, with clinical trial initiation planned for mid-2026. In both NSG-PiZ mouse and humanized PiZ rat disease models, a single 0.5 mg/kg dose of the lipid nanoparticle-encapsulated therapy achieved over 90% mRNA correction, yielded a greater than 5-fold increase in total serum AAT levels with an M-AAT:Z-AAT ratio exceeding 99%, and maintained durable editing for up to 9 weeks. The data were presented October 10, 2025 in an oral presentation titled "Single-dose in vivo gene correction of AATD via LNP-delivered SyNTase editors" at the European Society of Gene and Cell Therapy 2025 Annual Congress. "Alpha-1 antitrypsin deficiency remains an area of significant unmet need, with current treatments unable to address the underlying genetic cause. The goal of therapy should be to normalize alpha-1 antitrypsin levels," said Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics. "The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency. The data support CTX460's potential best-in-class profile in AATD, and we look forward to advancing CTX460 into the clinic in mid-2026." AATD affects patients carrying two copies of the PiZ variant (ZZ genotype) who typically maintain serum AAT levels of only 5-6 mM compared to normal levels exceeding 20 mM, leaving lungs vulnerable to emphysema while misfolded Z-AAT polymers accumulate in the liver contributing to fibrosis and cirrhosis. Current standard-of-care requires weekly intravenous infusions of purified M-AAT protein to mitigate lung symptoms without addressing the genetic cause, creating demand for therapies that normalize AAT levels to prevent disease progression. CTX460 represents the first investigational candidate to emerge from the SyNTase editing platform, with CRISPR Therapeutics positioning the technology as applicable to both rare and common disorders beyond AATD. Sources: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. -- SOURCES CITED 1. https://medicalxpress.com/news/2025-10-longevity-gene-supercentenarians-disease-rapid.html 2. https://www.globenewswire.com/news-release/2025/10/10/3164756/0/en/United-States-Artificial-Intelligence-in-Diagnostics-Market-Research-Report-2025-2033-Precision-Medicine-Advanced-Imaging-Analytics-and-AI-Enabled-Clinical-Decision-Support-Spur-Ex.html 3. https://www.globenewswire.com/news-release/2025/10/10/3164977/0/en/Precision-Medicine-Market-Size-Booms-at-16-35-CAGR-Expected-to-Reach-USD-463-11-Billion-by-2034.html